LRMR Larimar Therapeutics, Inc.Stock Price & Overview
$7.27
Charts
Quant Ranking
LRMR Analysis
LRMR News
Latest Headlines
Ratings Summary
People Also Follow
Similar to LRMR
ETFs Holding LRMR
LRMR Company Profile
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
LRMR Revenue
LRMR Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Profitability
Momentum
Capital Structure
Dividends
LRMR Ownership
LRMR Peers
Risk
Technicals
LRMR Transcripts
Investor Presentations
LRMR SEC Filings
Press Releases
LRMR Income Statement
LRMR Balance Sheet
LRMR Cash Flow Statement
LRMR Long Term Solvency
Discover More
You may be interested in: